Folate receptor alpha expression in uterine serous carcinoma: a single-institution analysis.
- 1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Michigan, 1500 E. Medical Center Dr., Ann Arbor, MI 48109, USA.
- 2Department of Pathology, University of Michigan, 1500 E. Medical Center Dr., Ann Arbor, MI 48109, USA.
Abstract
Uterine serous carcinoma (USC) is an aggressive histologic subtype of endometrial cancer for which limited targeted therapeutic options exist. Folate receptor alpha (FOLRα) is an established therapeutic target in high-grade serous ovarian carcinoma, but its expression patterns in USC remain poorly characterized. We sought to evaluate the prevalence and distribution of FOLRα expression in USC and assess the applicability of ovarian cancer-derived FOLRα thresholds to this histology. We conducted a retrospective review of patients with pathologically confirmed USC treated at a single institution from 2017 to 2024. FOLRα expression was assessed using the VENTANA FOLR1 (FOLR1-2.1) RxDx assay. Positivity was defined as ≥75% of tumor cells demonstrating moderate-to-strong membranous staining (PS2+ scoring). Seventy-three patients were included. Median age was 71 years; 53% had uterine-confined disease at presentation. In our cohort, nine tumors (12.3%) met the high-expression threshold for FOLRα positivity. An additional 13 tumors (17.8%) demonstrated intermediate expression, while 69.9% showed <50% staining. FOLRα expression in USC is variable, and only a minority of tumors met the high-expression threshold used for mirvetuximab soravtansine (MIRV) eligibility in ovarian cancer. However, nearly one-third demonstrated medium-to-high expression, suggesting that FOLRα targeting may not be fully captured by ovarian cancer-derived biomarker cutoffs in this disease process. These descriptive, hypothesis-generating findings support further evaluation of FOLRα-directed strategies, including combination approaches, in prospective studies of USC.
Related
- Activation of a STAT3/LATS1 Signaling Axis by Folate Receptor α Enables Breast Cancer Cells to Resist Physiological Ferroptotic Stress
- Investigation of the significance and role of androgen receptor expression in basal/squamous type urothelial carcinoma cell line J82 cells
- Cellular uptake of folate-olaparib conjugates via folate receptor-mediated endocytosis: Potential for selective delivery of DNA damage response inhibitors into tumour cells
- Validation of a Highly Specific Anti-Human Folate Receptor Alpha Single-Domain Antibody for Rapid Fluorescence-Guided Surgery of Ovarian and Lung Cancer
- Multimodal Detection of a Minute Uterine Cornual Lesion in Cervical Clear Cell Carcinoma
BibTeX
@article{batra2026folate,
title = {{Folate receptor alpha expression in uterine serous carcinoma: a single-institution analysis.}},
author = {Sadhvi Batra and Tao Huang and Stephanie Skala and Bori Lesser-Lee and Shitanshu Uppal and Zhen Ni Zhou},
journal = {Gynecologic oncology reports},
year = {2026},
month = oct,
doi = {10.1016/j.gore.2026.102230},
url = {https://europepmc.org/article/MED/42894871},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Folate receptor alpha expression in uterine serous carcinoma: a single-institution analysis.
AU - Sadhvi Batra
AU - Tao Huang
AU - Stephanie Skala
AU - Bori Lesser-Lee
AU - Shitanshu Uppal
AU - Zhen Ni Zhou
PY - 2026
DA - 2026/10/08
JO - Gynecologic oncology reports
DO - 10.1016/j.gore.2026.102230
UR - https://europepmc.org/article/MED/42894871
AB - Uterine serous carcinoma (USC) is an aggressive histologic subtype of endometrial cancer for which limited targeted therapeutic options exist. Folate receptor alpha (FOLRα) is an established therapeutic target in high-grade serous ovarian carcinoma, but its expression patterns in USC remain poorly characterized. We sought to evaluate the prevalence and distribution of FOLRα expression in USC and assess the applicability of ovarian cancer-derived FOLRα thresholds to this histology. We conducted a retrospective review of patients with pathologically confirmed USC treated at a single institution from 2017 to 2024. FOLRα expression was assessed using the VENTANA FOLR1 (FOLR1-2.1) RxDx assay. Positivity was defined as ≥75% of tumor cells demonstrating moderate-to-strong membranous staining (PS2+ scoring). Seventy-three patients were included. Median age was 71 years; 53% had uterine-confined disease at presentation. In our cohort, nine tumors (12.3%) met the high-expression threshold for FOLRα positivity. An additional 13 tumors (17.8%) demonstrated intermediate expression, while 69.9% showed <50% staining. FOLRα expression in USC is variable, and only a minority of tumors met the high-expression threshold used for mirvetuximab soravtansine (MIRV) eligibility in ovarian cancer. However, nearly one-third demonstrated medium-to-high expression, suggesting that FOLRα targeting may not be fully captured by ovarian cancer-derived biomarker cutoffs in this disease process. These descriptive, hypothesis-generating findings support further evaluation of FOLRα-directed strategies, including combination approaches, in prospective studies of USC.
SN - 2352-5789
ER -